CO6341637A2 - \\\\\\\"composiciones y metodos novedosos\\\\\\\" - Google Patents

\\\\\\\"composiciones y metodos novedosos\\\\\\\"

Info

Publication number
CO6341637A2
CO6341637A2 CO11009231A CO11009231A CO6341637A2 CO 6341637 A2 CO6341637 A2 CO 6341637A2 CO 11009231 A CO11009231 A CO 11009231A CO 11009231 A CO11009231 A CO 11009231A CO 6341637 A2 CO6341637 A2 CO 6341637A2
Authority
CO
Colombia
Prior art keywords
methods
rv3616c
new compositions
protein sequence
prevention
Prior art date
Application number
CO11009231A
Other languages
English (en)
Spanish (es)
Inventor
James E Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6341637A2 publication Critical patent/CO6341637A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CO11009231A 2008-07-25 2011-01-27 \\\\\\\"composiciones y metodos novedosos\\\\\\\" CO6341637A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
CO6341637A2 true CO6341637A2 (es) 2011-11-21

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009231A CO6341637A2 (es) 2008-07-25 2011-01-27 \\\\\\\"composiciones y metodos novedosos\\\\\\\"

Country Status (24)

Country Link
US (2) US20110117119A1 (cg-RX-API-DMAC7.html)
EP (1) EP2315773B1 (cg-RX-API-DMAC7.html)
JP (1) JP5873332B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110044883A (cg-RX-API-DMAC7.html)
CN (1) CN102164952B (cg-RX-API-DMAC7.html)
AU (1) AU2009273130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731499C (cg-RX-API-DMAC7.html)
CO (1) CO6341637A2 (cg-RX-API-DMAC7.html)
CY (1) CY1118200T1 (cg-RX-API-DMAC7.html)
DK (1) DK2315773T3 (cg-RX-API-DMAC7.html)
EA (1) EA024826B1 (cg-RX-API-DMAC7.html)
ES (1) ES2602430T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161458T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031044T2 (cg-RX-API-DMAC7.html)
IL (1) IL210559A0 (cg-RX-API-DMAC7.html)
LT (1) LT2315773T (cg-RX-API-DMAC7.html)
MX (1) MX2011000983A (cg-RX-API-DMAC7.html)
PL (1) PL2315773T3 (cg-RX-API-DMAC7.html)
PT (1) PT2315773T (cg-RX-API-DMAC7.html)
SG (1) SG192456A1 (cg-RX-API-DMAC7.html)
SI (1) SI2315773T1 (cg-RX-API-DMAC7.html)
UA (1) UA107330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010010177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026248A2 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
LT2315834T (lt) 2008-07-25 2018-09-10 Glaxosmithkline Biologicals S.A. Tuberkuliozės rv2386c baltymas, kompozicijos ir jų panaudojimas
ES2647321T3 (es) 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
JP6857029B2 (ja) 2013-09-27 2021-04-14 コデクシス, インコーポレイテッド 酵素バリアントの自動スクリーニング
HUE048104T2 (hu) * 2013-09-27 2020-05-28 Codexis Inc Szerkezet alapú prediktív modellezés
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CA3252762A1 (en) 2019-04-12 2025-07-08 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
DK2133100T3 (da) * 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
CN1277843C (zh) * 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
EP2380589A3 (en) * 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni

Also Published As

Publication number Publication date
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HUE031044T2 (en) 2017-06-28
CN102164952A (zh) 2011-08-24
PL2315773T3 (pl) 2017-07-31
ES2602430T3 (es) 2017-02-21
AU2009273130A1 (en) 2010-01-28
UA107330C2 (uk) 2014-12-25
SG192456A1 (en) 2013-08-30
EP2315773B1 (en) 2016-08-24
EA201100072A1 (ru) 2011-10-31
DK2315773T3 (en) 2016-12-12
CA2731499A1 (en) 2010-01-28
HRP20161458T1 (hr) 2016-12-16
CY1118200T1 (el) 2017-06-28
JP2011528895A (ja) 2011-12-01
US20110117119A1 (en) 2011-05-19
CN102164952B (zh) 2016-05-25
EA024826B1 (ru) 2016-10-31
LT2315773T (lt) 2016-11-10
KR20110044883A (ko) 2011-05-02
BRPI0916703A2 (pt) 2019-12-24
PT2315773T (pt) 2016-11-23
MX2011000983A (es) 2011-03-02
EP2315773A1 (en) 2011-05-04
SI2315773T1 (sl) 2016-12-30
US20140178423A1 (en) 2014-06-26
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
US9795663B2 (en) 2017-10-24
CA2731499C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CO6400198A2 (es) Composiciones y metodos novedosos
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BR112014007675A2 (pt) tratamento de doença articular degenerativa
AR084285A1 (es) Composiciones inmunogenicas
ECSP077261A (es) Composición de anticuerpo her2
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
AR080914A1 (es) Proteinas de union al beta-amiloide
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
ATE404225T1 (de) Radiofluorierte peptide
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112012015188A2 (pt) "composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese"
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden

Legal Events

Date Code Title Description
FC Application refused